Globally, traumatic brain injury (TBI) and stroke are the primary contributors to mortality and disability. In recent years, C-C chemokine receptor 5 (CCR5) has attracted much attention as a potential therapeutic target for stroke and TBI. Therefore, we performed a meta-analysis of animal models of stroke or TBI to assess the therapeutic effects of CCR5 inhibition. The PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), VIP Chinese Journal Service Platform (VIP), Ovid MEDLINE, Wanfang Data Knowledge Service Platform (Wanfang), and China Biomedical Literature Database (CBM) databases were searched, and twelve studies were included. The program Stata 17.0 was used to perform the statistical analysis. Overall, the results revealed that CCR5 inhibition reduced infarct volume, neurological deficit scores, and microglial activation and increased cAMP response element-binding protein (CREB) expression levels in animal models of stroke or TBI; however, there was no significant effect on astrocytes or the number of apoptotic cells. Subgroup analyses revealed that inhibition of CCR5 was more effective at reducing lesion volume in animal models of TBI, with CCR5 inhibitors, after the onset of stroke or TBI, and at intervention durations of 1-3 days. Furthermore, the results of this study suggest that the CCR5/PKA/CREB signaling pathway may be involved in the treatment of stroke and traumatic brain injury. These results suggest that CCR5 inhibition may have significant therapeutic uses in the management of TBI and stroke. However, further preclinical research is needed to assess the safety and effectiveness of CCR5 inhibitors with greater accuracy.
[1]Jilin Univ, Coll Basic Med Sci, Dept Histol & Embryol, Changchun 130021, Jilin, Peoples R China.
[2]Jilin Univ, China Japan Union Hosp, Reprod Med Ctr, Changchun 130033, Jilin, Peoples R China.
[3]Tumor Hosp Mudanjiang City, Dept Clin Lab, Mudanjiang 157009, Heilongjiang, Peoples R China.
(8.0+极速模式)